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heparin-induced thrombocytopeniaIn theory,most laboratory tests for immune heparin-induced throm-
bocytopenia (HIT) can beperformedwithin a fewhours of blood sample
acquisition. But for the most common type of test performed – the
platelet factor 4 (PF4)-dependent enzyme-linked immunosorbent
assay (ELISA) – the blood samples are almost always tested in batches,
at most once-daily (and often not on weekends), and so results are
frequently not available to the clinician until 1–4 days later. More deﬁn-
itive tests for detecting HIT antibodies (with greater diagnostic speciﬁc-
ity), such as certain platelet activation assays, are performed by
relatively few centers, and thus there is an additional time delay that re-
ﬂects sample delivery to a different facility that could even be in another
state or province. Even at my own medical center, with an excellent
assay for HIT (the platelet serotonin-release assay), testing is performed
just twice-weekly (Tuesdays and Thursdays, with results reported
Wednesdays and Fridays, respectively), meaning that a turnaround of
up to several days is common [1].
But some PF4-dependent immunoassays have been speciﬁcally de-
signed for rapid turnaround, deﬁned as 30 min or less [2]. Moreover,
such “on-demand” tests are engineered for evaluation of single blood
specimens. Thus, if such an assay is available on-site at a laboratory lo-
cated within (or near) a clinical institution, there is the prospect for a
speedy test result within a relatively short period of time. Rapid, on-
demand assays for HIT that have been developed include automated
tests requiring proprietary machines, such as the HemosIL® HIT-
Ab(PF4\\H) (performed using an ACL TOP® hemostasis analyzer; Instru-
mentation Laboratory, Bedford, MA) [3,4], the HemosIL AcuStar HIT-
IgG(PF4\\H) and HemosIL AcuStar HIT-Ab(PF4\\H) (IgG-speciﬁc and
polyspeciﬁc fully-automated chemiluminescence assays, respectively,
using the ACL AcuStar™ hemostasis testing system) [4,5], the particle
gel immunoassay (PaGIA; H/PF4-PaGIA®, Bio\\Rad,Marne La Coquette,
France), using standard blood bank centrifugation equipment [6,7], and
the lateral ﬂow immunoassay (STic Expert® HIT, Diagnostica Stago,
Asnières sur Seine, France) [8,9]. (Although another on-demand assay
– the particle immunoﬁltration assay (PIFA®; Akers Biosciences,
Thorofare, NJ) – is marketed, this test has poor operating characteristics
[10], and its use for HIT diagnosis is problematic [11].)
In this issue of Thrombosis Research, Caton and colleagues [12] have
performed a literature review and conducted semi-structured inter-
views and surveys evaluating various diagnostic and treatment
strategies for different HIT laboratory tests. They then modeled the
frequency and overall costs associated with various adverse HIT-
related outcomes, such as bleeding and thrombosis, for different test ap-
proaches. The authors concluded that “modeling estimated more HIT-
related [adverse] outcomes for patients maintained on heparin whilst
awaiting test results and patients switched onto replacement anticoag-
ulant therapy awaiting test results, compared with on-demand testinghttp://dx.doi.org/10.1016/j.thromres.2016.02.015
0049-3848/© 2016 The Author. Published by Elsevier Ltd. This is an open access article underand treatment based on these results.” The authors further noted that
a “budget impact model estimated that on-demand testing reduced re-
placement anticoagulant therapy costs from $39,616 to $12,799 per pa-
tient.” Do these claims withstand scrutiny?
Consider some truisms regarding HIT:
(a) only 5% to 10% of patients investigated for HIT with laboratory
testing ultimately are shown to have this diagnosis, using a
washed platelet activation test as the reference standard [13,14];
(b) anticoagulants widely approved for treatment of HIT, such as
argatroban and danaparoid, are relatively expensive (note:
danaparoid is not approved for treatment of HIT in the U.S.), es-
pecially compared to the cost of maintaining (or switching back
to) unfractionated heparin, a very inexpensive medication;
(c) the frequency ofmajor hemorrhage using the direct thrombin in-
hibitors approved for HIT (argatroban, lepirudin) are approxi-
mately 1% per treatment-day [15] (note: lepirudin is no longer
marketed and thus is not available for treating HIT);
(d) the thrombosis rate is approximately 5–10% per day, for at least
the ﬁrst 2 or 3 days, if heparin is held in a patient who is subse-
quently conﬁrmed to have HIT by a positive washed platelet ac-
tivation assay [16].
Given that there are signiﬁcant costs associated with bleeding and/
or thrombotic events, not tomention the human cost of relatedmorbid-
ities andmortality, it would seem that the conclusions of Caton and col-
leagues are likely to be correct. Based upon evolving concepts inHIT, the
following statements should reﬂect the potential clinical value of on-
demand testing for HIT antibodies:
(a) a negative result using an on-demand assay would avoid the ex-
pense and bleeding risks associated with initiating therapy with
an alternative non-heparin anticoagulant, provided that the di-
agnostic sensitivity of the on-demand assay is sufﬁciently good
to ensure a high negative-predictive value.
(b) a positive result using an on-demand assay would justify the ex-
pense and bleeding risks associated with initiating therapy with
an alternative non-heparin anticoagulant, provided that the
false-positive rate is not excessively high.
(c) assays that provide semi-quantitative results, in other words,
weak-, moderate- or strong-positive results that correspond to
comparatively greater probability of (platelet-activating) HIT an-
tibodies being detectable, can provide graded likelihood ratios,
which are useful for reﬁning the clinician's post-test estimation
of a patient having (or not having) HIT. For example, a patient
judged to have an intermediate or high probability of HIT canthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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quantitative immunoassay) yields a result that is strongly positive.
To express this in Bayesian post-test probability terms, a blood
sample obtained from a patient with clinically-suspected HIT
who has a positive polyspeciﬁc anti-PF4/polyanion ELISA of great-
er than 2.0 optical density units has a probability of conﬁrmed HIT
that ranges from 90% (with an intermediate pre-test probability)
to 99% (based on a high pre-test probability) [17,18].
How can these concepts apply to on-demand testing? The HemosIL
automated assays routinely provide results expressed quantitatively
(i.e., units per milliliter), and it therefore will be important to examine
the positive predictive values of different strengths of positive results
(in comparison with the negative predictive values of negative test re-
sults), at varying degrees of pre-test probability (e.g., as predicted by a
clinical scoring system for HIT such as the 4Ts [7,19]). The three
HemosIL assays' outputs are termed “semi-quantitative”, as there is no
absolute linear correlation between the degree of positive test results
and differing levels of HIT antibodies. Nevertheless, it is known that
other semi-quantitative assays, such as the PF4-dependent ELISAs, pro-
vide enormously valuable information beyondmerely providing a “pos-
itive” or “negative” result. For example, if an ELISA is “positive” but only
weakly so (i.e., 0.40 to 0.99 OD units), the patient has less than a 5%
chance of having HIT; conversely, if the ELISA result is greater than 2.0
units, the probability of the patient having HIT is at least 90%. The
PaGIA test, by way of contrast, provides only a dichotomous result
(positive or negative); however, even the PaGIA can be made semi-
quantitative by performing the assay using various blood sample dilu-
tions; here, a positive result using patient plasma diluted 1/4 or greater
predictsmore strongly for HIT than a test that is positive using only neat
(undiluted) plasma [20].
The study by Caton and colleagues indicates that on-demand testing
is likely to hasten diagnostic evaluation of patients with suspected HIT,
contributing to substantial cost savings and possibly also to improved
outcomes. Future research that examines also the impact of interpreting
the speciﬁc numerical results of the semi-quantitative on-demand as-
says should demonstrate more accurate assessment of the post-test
probability of HIT. This will improve clinical decision-making, for exam-
ple, in cases of relatively high probability clearly justifying the switch
from heparin to a different anticoagulant, while at the same time iden-
tifying low-probability situations that will avoid unnecessary use of
expensive and risky anticoagulants with a high chance of causing bleed-
ing. Before long, clinicians will demand on-demand testing for their
patients.
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